September 2013, Vol 2, No 6
Illustrating the New Era of Personalized MedicineLetter to Our Readers
It gives us great pleasure to present this issue of Personalized Medicine in Oncology (PMO). Over the past several months, we have thoroughly examined every aspect of the journal – appearance, readability, and most importantly, editorial content.
You will see the result of our efforts in the following ways:
The immune system is back in the discussion of how to fight cancer. Many exciting new agents are being studied in clinical trials in diseases such as non–small cell lung cancer, melanoma, and kidney cancer, to name just a few. PMO will keep readers up to date on advances in this area and discuss what it means for patients.
• Interview With the Innovators
The world of personalized medicine is a rapidly changing, ever-evolving state involving many stakeholders on the front lines of its creation: physicians, industry, researchers, patient advocates, and payers. PMO seeks out the leaders in these sectors and brings you their game-changing strategies, missions, and impact on personalized oncology care.
• The Last Word
In this department, our Strategic Editor and Editor in Chief sum up thoughts on various overriding themes in the world of personalized medicine.
• Journal Design
You will notice a redesign in the look of the entire journal. This new, streamlined design is intended to make the journal easier to read and navigate.
We believe these will greatly enhance your reading experience. Please let us know what you think! E-mail our Editorial Director, Kristin Siyahian at firstname.lastname@example.org. We look forward to and welcome your feedback.
Al Benson, MD
Editor in Chief
Personalized Medicine in Oncology
Genomic Sequencing Uncovers the Genetic Landscape of Primary CNS Lymphoma: Will likely lead to new targeted therapies for an incurable malignancy
Lugano, Switzerland – The genomic basis of primary central nervous system lymphoma (PCNSL), a very aggressive and incurable type of lymphoma, has not been understood until now. At the 2013 International Conference on Malignant Lymphoma, a team of researchers from the Mayo Clinic and from the University of Virginia presented [ Read More ]
Olaparib maintenance therapy prolonged progression-free survival (PFS) and the time to disease progression after a second subsequent therapy (PFS2) in patients with platinum-sensitive relapsed serous ovarian cancer (SOC). The effect of olaparib was particularly robust in patients with a BRCA mutation in an updated analysis of Study 19 presented at [ Read More ]